Il programma nazionale australiano di test point-of-care per l'HCV - Set di dati minimo
Il programma nazionale australiano di test point-of-care per l'HCV: uno studio di coorte osservazionale per valutare l'uso del test dell'epatite C point-of-care tramite puntura del dito per migliorare la diagnosi e il trattamento dell'infezione da HCV - Set di dati minimo
The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The advent of simple direct-acting antiviral hepatitis C (HCV) therapies with cure rates >95% is one of the greatest medical advances in decades, having led to a reversal in liver-related mortality. In Australia, treatment uptake has declined between 2016 (32,000 treated) and 2019/20 (2019: 11,500; 2020: 8,500).1 Progress towards HCV elimination has been impeded by COVID-19, affecting the delivery of national and state-based HCV strategies. Improving HCV treatment uptake to reduce disease burden is a key aim of global, national and state-based HCV strategies.2-4
Scale-up of HCV testing and treatment will be required to achieve elimination by 2030. Current diagnostic pathways require multiple visits to a practitioner reducing the proportion who receive a diagnosis. In Australia, 81% of people have had HCV antibody testing (indicates exposure), but only 47% have been HCV RNA tested (indicates active infection and the need for HCV treatment).5 Mathematical modelling suggests that HCV RNA testing needs to increase by at least 50% annually to achieve elimination in Australia by 2030.6
The Kirby Institute is an international leader in research evaluating the Xpert HCV assay (Grebely Lancet Gastro Hep 2017), having built a large network of Xpert platforms for HCV testing in needle and syringe programs, prisons, drug treatment clinics, tertiary hospitals, and Aboriginal Community Controlled Health Service. In Kirby-led research, point-of-care HCV testing interventions in needle and syringe programs and prisons have resulted in high HCV treatment uptake (70-90%). The Kirby Institute and Flinders University also have a strong track record of implementing point-of-care testing for STIs and COVID-19, providing an ideal foundation to scale-up Xpert HCV testing in Australia.
The Kirby Institute and Flinders University will establish the Australian National HCV Point-of-care Testing Program for the scale-up of point-of-care HCV RNA testing in services with high prevalence of HCV infection, including community health centres, drug treatment clinics, needle and syringe programs, and prisons. This program will include the development of standard operating procedures, logistics/deployment, initial set-up, an operator training program, and quality assurance and competency assessment program.
An observational cohort study will be established to evaluate HCV treatment uptake following scale-up of point-of-care HCV testing among people with a risk factor for acquisition of HCV infection or people attending a service caring for people with risk factors for the acquisition of HCV infection.
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. All participants who undergo point-of-care HCV testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care for any other clinical assessments and treatment initiation.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Simon Comben, BSc, MN
- Numero di telefono: +6193480777
- Email: scomben@kirby.unsw.edu.au
Backup dei contatti dello studio
- Nome: David Silk, BSc
- Numero di telefono: +61293850900
- Email: dsilk@kirby.unsw.edu.au
Luoghi di studio
-
-
New South Wales
-
Sydney, New South Wales, Australia
- Attivo, non reclutante
- Justice Health and Forensic Mental Health Network
-
-
Queensland
-
Aldershot, Queensland, Australia, 4650
- Reclutamento
- Maryborough Correctional Centre
-
Contatto:
- Ashley Willman
- Numero di telefono: (07) 4123 7600
- Email: ashley.willmann@health.qld.gov.au
-
Brisbane, Queensland, Australia, 4000
- Reclutamento
- QuIHN
-
Contatto:
- Nicholas Alexander
- Numero di telefono: 3620 8111
- Email: nalexander@quihn.org
-
Cairns, Queensland, Australia
- Reclutamento
- Lotus Glen Correctional Centre
-
Contatto:
- Darren Russell
-
Investigatore principale:
- Darren Russell
-
Coorparoo, Queensland, Australia, 4151
- Completato
- Hepatitis Queensland
-
Ipswich, Queensland, Australia
- Reclutamento
- West Moreton Hospital and Health Service
-
Contatto:
- Blake Ponting
-
Investigatore principale:
- Blake Ponting
-
Rathdowney, Queensland, Australia, 4287
- Non ancora reclutamento
- Palen Creek Correctional Centre
-
Contatto:
- Mike Hurley
- Numero di telefono: (07) 5544 3700
- Email: mike.hurley@corrections.qld.gov.au
-
Townsville, Queensland, Australia
- Reclutamento
- Townsville Correctional Centre
-
Contatto:
- John Morey
-
Investigatore principale:
- John Morey
-
Woodford, Queensland, Australia
- Reclutamento
- Woodford Correctional Centre
-
Contatto:
- Rajendra Prakash
-
Investigatore principale:
- Rajendra Prakash
-
-
South Australia
-
Hackney, South Australia, Australia, 5069
- Reclutamento
- Hepatitis SA
-
Contatto:
- Lisa Carter
- Numero di telefono: (08) 8362 8443
- Email: lisa@hepatitissa.asn.au
-
Marden, South Australia, Australia, 5070
- Non ancora reclutamento
- South Australian Prison Health Service
-
Contatto:
- Tom Turnbull
-
Investigatore principale:
- Tom Turnbull
-
Mount Gambier, South Australia, Australia, 5290
- Reclutamento
- Mount Gambier Priosn
-
Contatto:
- William Galloway
-
Investigatore principale:
- William Galloway
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- Attivo, non reclutante
- St Vincent's Correctional Health Services
-
Melbourne, Victoria, Australia, 3000
- Reclutamento
- Medically Supervised Injecting Room
-
Contatto:
- Nathan Stam
-
Investigatore principale:
- Nathan Stam
-
Ravenhall, Victoria, Australia, 3023
- Reclutamento
- Dame Phyllis Frost Centre
-
Contatto:
- Katelyn Mannix
- Numero di telefono: 1300 492 202
- Email: katelyn.mannix@wh.org.au
-
Ravenhall, Victoria, Australia, 3023
- Reclutamento
- Geo Healthcare - The Geo Group Australia Pty Ltd
-
Contatto:
- David Grace
-
Investigatore principale:
- David Grace
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.
Descrizione
Inclusion Criteria:
- ≥ 18 years of age.
- Received point-of-care HCV testing.
Exclusion Criteria:
- Nil
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
People at risk of HCV acquisition
Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing. |
Participants will be offered finger-stick point-of-care testing for HCV |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The proportion of HCV infected participants who initiate HCV treatment at 12 weeks
Lasso di tempo: 12 Weeks from enrolment
|
To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing. |
12 Weeks from enrolment
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The proportion of participants who accept point-of-care testing
Lasso di tempo: 2 years from recruitment commencement
|
To evaluate the proportion of people who accept point-of-care testing among those offered testing. |
2 years from recruitment commencement
|
|
The prevalence of HCV infection amongst study participants tested
Lasso di tempo: 2 years from recruitment commencement
|
To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested. |
2 years from recruitment commencement
|
|
To evaluate the time to HCV treatment uptake among HCV RNA positive participants
Lasso di tempo: 52 weeks
|
To evaluate the length of time participants take to initiate HCV treatment after diagnosis |
52 weeks
|
|
To evaluate proportion of HCV RNA positive participants who initiate HCV treatment
Lasso di tempo: 52 weeks
|
To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
|
To evaluate the proportion of participants who complete HCV (DAA) treatment
Lasso di tempo: 52 weeks
|
To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment. |
52 weeks
|
|
To evaluate the proportion of participants who achieve an SVR
Lasso di tempo: 12 weeks
|
To evaluate the proportion of participants who achieve an SVR (defined as HCV RNA below the lower limit of quantitation at post treatment week 12). |
12 weeks
|
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months
Lasso di tempo: 52 weeks
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- VHCRP2104
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Request to share IPD will be considered by the protocol steering committee on individual basis
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .